In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sunovion CNS Development Canada ULC

Division of Sumitomo Chemical Co.
www.cynapsus.ca

Latest From Sunovion CNS Development Canada ULC

Sumitomo Dainippon Shores Business/Pipeline Ahead Of Latuda Cliff

Facing the looming loss of exclusivity for its top product, Sumitomo Dainippon Pharma is looking to its late-stage pipeline and recent product and corporate acquisitions to help plug the hole.

Commercial Strategy

PIPELINE WATCH: Nine Approvals, Eight Filings And Three Launches

This week's Pipeline Watch, a snapshot of all the late-stage R&D and regulatory events in the pharma and biotech industries, is now available to view.

Pipeline Watch Approvals

Sunovion Adds Parkinson's To CNS Franchise With Cynapsus Buyout

Sumitomo Dainippon unit pays a 123% premium to acquire Cynapsus and its Phase III Parkinson's drug APL-130277, with at least one analyst speculating it paid a high price in order to avoid a bidding war.

Neurology Deals

Deals Shaping The Medical Industry, May 2016

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, Pharmaceuticals, and Research/Analytical Supplies – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in April 2016.

BioPharmaceutical Medical Device
See All

Company Information

UsernamePublicRestriction

Register